-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propranolol Hydrochloride in Retinopathy Of Prematurity
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Propranolol Hydrochloride in Retinopathy Of Prematurity Drug Details:Propranolol hydrochloride (REC-0551) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)Drug Details:Losmapimod (GW-856553X) is under development...
-
Company Insights
Innovation and Patenting activity of Fulcrum Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fulcrum Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Fulcrum Therapeutics Inc – Company Profile
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company. The company is involved in the discovery and development of small molecule therapies to unlock gene regulation in diseases. Its pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease. The company also owns a proprietary product engine FulcrumSeek, which detects drug targets that can control gene expression and treat the root cause of gene misexpression. The company’s key therapeutic areas include neuromuscular,...
Add to Basket -
Product Insights
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein (SNCA) Drugs in Development Report Overview Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route...
-
Product Insights
Net Present Value Model: Losmapimod
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Losmapimod Drug Details Losmapimod (GW-856553X) is...
-
Product Insights
Net Present Value Model: FTX-6058
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model FTX-6058 Drug Details Small molecule is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FTX-6058
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FTX-6058 Drug Details Small molecule is under development for the treatment of sickle cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – losmapimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry losmapimod Drug Details Losmapimod (GW-856553X) is under development for the treatment of facioscapulohumeral muscular...
-
Product Insights
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscular Dystrophy Pipeline Drugs Market Report Overview Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of...